SF Healthcare Week: Bluejay Therapeutics' CEO Keting Chu talks about what led to the the successful $620M+ acquisition of her company and its chronic hepatitis delta virus antibody by Mirum

Jan 14
1 min read

Updated: Jan 17

She discusses the profile of the drug, which is currently in a phase 3 study, and the data Bluejay had previously presented on it. Plus, her advice for other entrepreneurs who might be fielding bids.

https://vimeo.com/1155587989

Recent Posts

See All

BIO 2026: Nkarta will have key data by the end of the year from its NK cell therapy approach in a host of autoimmune conditions

BIO 2026: COUR Pharma last week raised a $50M series B to progress its nanoparticle approach to reprogramming the immune system to treat type 1 diabetes

BIO 2026: Enveda's AI discovery platform leans heavy on chemistry and learnings from Mother Nature - the lead clinical program to come out of it is focused on atopic derm

SF Healthcare Week: Bluejay Therapeutics' CEO Keting Chu talks about what led to the the successful $620M+ acquisition of her company and its chronic hepatitis delta virus antibody by Mirum

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight